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Abstract: Complement is one of the integral but-
tresses of the inflammatory response. In addition to
host defense activities, proinflammatory properties
of several complement components are described.
This overview elucidates the role of complement in
inflammatory reactions in vitro and in vivo, focus-
ing on the complement activation products, C5a,
and the membrane attack complex, C5b-9. Using
several approaches, the impact of these comple-
ment components in mechanisms relevant to neutro-
phil recruitment is emphasized. In addition, the
participation of complement in endothelial superox-
ide generation and its essential requirement for full
expression of lung injury is demonstrated, as are
the involved intracellular signal transduction path-
ways. Understanding the mechanisms of comple-
ment-induced proinflammatory effects may pro-
vide a basis for future therapeutic blockade of
complement and/or its activation products. J. Leu-
koc. Biol. 64: 40–48; 1998.
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INTRODUCTION
The role of the complement system as an integral part of the
host defense response is well known. Functions like facilitation
in clearance of circulating immune complexes and their
opsonization, platelet aggregation and histamine release in-
duced by anaphylatoxins as well as chemotactic activity of C5a,
and the cell lysing capability of distal complement components,
which form the membrane attack complex (MAC, C5b-9), have
been studied in detail. The essential requirements of comple-
ment for clearance of and/or resistance to the biological effects
of microorganisms or bacterial endotoxin have been reported for
complement components C3, C4, and C6, demonstrating higher
sensitivity to endotoxin in animals deficient in either of these
complement factors [1–5]. Also well established but not well
understood is the involvement of the complement system in the
inflammatory response. Recent data suggest that the involve-
ment of complement in inflammation goes considerably beyond
the chemotactic recruitment of neutrophils. As will be empha-
sized in this review, complement activation products can
directly activate phagocytic cells as well as endothelial cells. In
this context, two components of the complement cascade, the
small activation product, C5a, and the functional unit of the
MAC, assume prominent roles.
In contrast to the effects of genetically determined deficien-
cies of the complement components (C3, C4, C6) and associ-
ated increased susceptibility to the harmful effects of endo-
toxin, mice deficient of C5 have been reported to be less
sensitive to the effects of intravenously infused endotoxin than
C5-sufficient animals, a finding that appears to be related to
lower serum tumor necrosis factor a (TNF-a) levels in the
C5-deficient animals [6]. Macrophages obtained from the same
C5-deficient mice showed a much reduced TNF-a response in
vitro after stimulation with endotoxin. This response has been
linked to the availability of the cleavage product C5a, since
recombinant C5a induced a nearly normal in vitro increase of
TNF-a responses of macrophages obtained from C5-deficient
mice. These results suggest that C5a has additional functions
that are distinctively different from the chemotactic properties
of C5a generated by the C5 convertase-induced cleavage of C5
after activation of the classical or alternative pathways of
complement. In other studies the role of C5 in inflammation has
been evaluated by employing an antibody to C5, preventing
generation of both C5a and the MAC. A significant amelioration
of lupus-like autoimmune disease was found in genetically
disposed mice as well as a markedly increased survival after C5
blockade occurred [7]. Similarly, anti-C5 antibody therapy
prevented collagen-induced arthritis in mice [8]. Treatment
with antibodies to C5 also prevented acute cardiac tissue injury
and inhibited hyperacute rejection of xenografted organs [9]. It
should be emphasized that, in addition to the complement-
generated C5 convertase, C5 can be cleaved into chemotactic
fragments by serine proteases such as trypsin and by trypsin-
like enzymes contained in neutrophil granules [10–12].
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In addition to activation of platelets, inducing their aggrega-
tion and secretion of serotonin, C5a is known to induce surface
expression of P-selectin on endothelial cells [13]. There is a
large body of evidence suggesting a substantial direct and
indirect role for C5a not only in the expression of endothelial
adhesion molecules but also for synthesis and release of
cytokines from activated macrophages (discussed below in
detail). Macrophages can synthesize C5 and may contain
enzymes capable of cleaving C5 to produce C5a. It appears that
C5a may serve as an autocrine activator of macrophages
through a positive feedback mechanism [B. J. Czermak and
P. A. Ward, unpublished observations]. With respect to MAC,
the cell-lysing ability of this complex is based on the ring-like
structure it forms in cell membranes [reviewed in ref. 14]. After
insertion of C5bC6 complex into cell membranes for which the
presence of C7 is required, C8 molecules and subsequently C9
molecules are incorporated into this complex, leading to pore
formation in phospholipid membranes. The extent of MAC-
induced damage as defined by cell lysis has been linked to the
number of C9 molecules inserted into this complex. Up to 16
C9 molecules have been described to arrange in these indi-
vidual ring lesions [15], with at least four C9 molecules being
necessary for each C5b-8 complex to form a lytic lesion through
which large intracellular molecules can pass to the exterior of
the cell, resulting in cytolysis [16]. In functional immunochemi-
cal assays, an average of three to four C9 molecules have been
shown to be bound per C5b-8 complex on MAC-lysed erythro-
cytes [17]. Although MAC lacking in C9 has some limited
biological functions similar to the MAC containing C9, these
functions represent only a fraction of those found in the fully
formed MAC. Nucleated cells show a higher resistance to lysis
by MAC, largely dependent on their metabolic state at any given
moment. In addition, the cell membrane content of complement
regulatory molecules [such as complement receptor-1, decay
accelerating factor (DAF), etc.] affects cell susceptibility to
lysis by MAC by regulating the generation of C3 and C5
convertases. As will be emphasized below, insertion into
endothelial cell membranes of MAC in sublytic concentrations
(containing a composition of less than three C9 molecules per
C5b-8 complex) results in cell activation events. It should be
pointed out that MAC has been detected both as serum sMAC
in humans with adult respiratory distress syndrome [18] and in
vascular endothelial cells of renal glomeruli in a variety of
models of glomerulonephritis [19]. Chemokine release from
endothelial cells treated with MAC further adds to the fairly
recently recognized proinflammatory role of complement, which
has triggered a revival of scientific interest in the complement
system.
The current review focuses on functions of the complement
activation products, C5a and MAC, in inflammatory reactions
in several in vitro and in vivo models, emphasizing the involvement
of complement in crucial steps of acute inflammatory reactions.
STRATEGIES FOR ASSESSMENT OF THE
BIOLOGICAL ROLES OF COMPLEMENT
Assessment of the biological roles of complement can be
achieved by a variety of approaches, including the in vitro use
of sera deficient in individual complement components, the use
of animals that are genetically deficient in complement compo-
nents (e.g., C3 or C5 in mice, C4 in guinea pigs, C6 in rabbits),
or the development of mutant (knockout) mice with specific
deficiencies (e.g., involving C3 or the C5a receptor, C5aR).
Another strategy features transgenic expression of products
such as DAF in animals, which has for example been empha-
sized as a way to avoid the hyperacute rejection that occurs in
xenografted organs. Finally, complement depletion (with cobra
venom factor) and complement blockade [with soluble comple-
ment receptor 1 (sCR1), anti-C5, anti-C5a, etc.] have been used
to define biological functions of the complement system.
Whereas many of these strategies are able to identify different
biological functions related to complement by interrupting the
activation of the complement cascade at different stages, they
often fail to precisely pinpoint which complement activation
products are most importantly associated with a complement-
dependent inflammatory reaction. For control of the comple-
ment system in inflammatory diseases in which complement
activation appears advantageous, it seems desirable to leave
certain functions (e.g., opsonization or bacterial lysis) largely
intact and to interfere with precisely targeted products of the
complement system. This can be accomplished by infusion of
adequate amounts of sCR1 to suppress but not absolutely block
activation of the complement system, much like the strategy
used in immunosuppression. Another strategy would be aimed
at specific blockade of a complement activation product,
provided it is clear which activation product is most relevant.
Such studies are facilitated by the availability of purified
complement components and specific antibodies to single
complement activation products. This review focuses on our
studies employing complement depletion, blockade of the
cleavage product of C5, C5a, and exogenous administration of
the complement activation product, C5a, as well as in vitro
assembly of MAC on cell membranes. As shown below, C5b-9 is
a functional unit, as demonstrated by the fact that MAC
assembled so as to be devoid of any one of the individual five
complement components is largely inactive in either cell lysis
or in its pro-inflammatory effects. It should also be emphasized
that single components of MAC are known to be functionally
inert as relevant to MAC-dependent responses.
Blockade of C5a has been made possible by availability of an
antibody that is reactive to rat C5a but not reactive with the
parent molecule, C5. This antibody was raised in rabbits and
goats that had been immunized with purified rat C5a. Using
immunoprecipitation techniques, C5a was detected as a band
near the 14 kDa marker, as defined in polyacrylamide gel
electrophoresis (PAGE). The same band was detected in
activated rat serum by Western blot analysis using anti-C5a, but
a band was not detectable in nonactivated serum [20]. A
nonspecific control antibody failed to show any evidence of
reactivity. The functional properties of the anti-C5a antibody
are demonstrated in Figure 1. The serum content of C5a after
systemic complement activation with cobra venom factor (CVF)
in rats rose within minutes to a maximal level of nearly 400
ng/mL (Fig. 1A). The chemotactic activity present in serum
(Fig. 1B) could be completely abolished with anti-C5a, indicat-
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ing that all chemotactic activity developing after intravenous
infusion of CVF can be assigned to C5a [21].
IN VITRO ENDOTHELIAL EXPRESSION
OF P-SELECTIN BY C5a AND MAC
To study the effects of C5a on endothelial cells, human
umbilical vein endothelial cells (HUVEC) were incubated with
increasing doses of human recombinant C5a. It was shown that
HUVEC contain mRNA for C5aR and binding studies have
indicated a high-affinity C5aR on HUVEC, although conditions
that result in up-regulation of C5aR have not been identified
[13]. Increased expression of P-selectin occurred on HUVEC
proportional to the concentration of C5a used (Fig. 2A). This
increased expression went hand-in-hand with enhanced neutro-
phil (PMN) adhesion to these treated HUVEC (Fig. 2B). A
time-course for P-selectin expression in HUVEC stimulated
with 250 nM C5a was demonstrated, occurring within minutes
and followed by the return to baseline levels within 30 min.
Again, P-selectin expression and neutrophil adhesion were very
closely related, with a peak of P-selectin production at 10 min
and a maximum of neutrophil adherence occurring after 15 min.
Similar P-selectin expression has been observed after assembly
of sublytic concentrations of the membrane attack complex on
HUVEC, with a similar time-course [K. S. Kilgore, unpub-
lished data]. These data are consistent with an earlier report in
which the addition of a complement fixing antibody to an
epitope on HUVEC in the presence of fresh human serum
resulted in P-selectin expression [22]. The role of P-selectin in
neutrophil adhesion to C5a-stimulated HUVEC was demon-
strated by the use of blocking monoclonal antibodies. An
antibody to P-selectin decreased the binding of neutrophils
to C5a-treated HUVEC, whereas blockade by antibody to
E-selectin, ICAM-1, or CD18, or a combination thereof, failed
to affect neutrophil adhesion (Fig. 3). The inability of anti-
CD18 and anti-ICAM-1 to affect this adhesion promoting
process appears to preclude the role of residual C5a present on
HUVEC surfaces, resulting in activation of PMN to bring about
up-regulation of PMN CD11b/CD18 (Mac-1), which could then
engage constitutive ICAM-1 on HUVEC in adhesive interac-
tions.
Fig. 2. Dose-response for C5a stimulation of HUVEC. Endothelial P-selectin expression (A) correlated well with biologically functional aspects, both P-selectin
expression and PMN adherence (B) being dependent on the dose of C5a administered.
Fig. 1. Serum content of C5a (A) and chemotactic activity (B) following systemic complement activation by intraperitoneal injection of CVF. Samples were obtained
via indwelling arterial catheters. Both antigenic and biological activities in serum could be totally suppressed by in vitro addition of anti-C5a to serum. Statistical
comparisons shown are to negative controls (A) and CVF 1 anti-C5a (B).
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LUNG VASCULAR EXPRESSION
OF P-SELECTIN AFTER SYSTEMIC
ACTIVATION OF COMPLEMENT
The ability of complement activation products to participate in
the in vivo expression of endothelial P-selectin expression was
demonstrated after systemic activation of complement following
bolus intravenous infusion of CVF into rats. This type of
systemic activation of complement results in acute focal
necrosis of lung vascular endothelial cells at points of contact
between intravascular PMN and pulmonary capillary endothe-
lial cells. The question arose as to whether circulating neutro-
phils, which are known to be involved in this injury process,
were recruited into lung in a P-selectin-dependent manner.
Based on the use of a blocking antibody to P-selectin, it is
known that neutrophil accumulation and ensuing lung injury
are P-selectin dependent [23]. Using fixation of 125I-anti-P-
selectin in order to quantitate lung vascular up-regulation of
P-selectin, lung vascular P-selectin was found to be up-
regulated within minutes after infusion of CVF, peaking at 20
min. The use of an irrelevant subclass matched murine
antibody (MOPC-21) demonstrated the lack of binding of this
control IgG (Fig. 4). The crucial requirement of complement
for expression of lung vascular P-selectin was assessed using
complement depletion procedures (after repetitive intraperito-
neal injections of CVF) or by intravenous treatment with anti-C5a
antibody. Both interventions resulted in complete abrogation of
up-regulation of lung vascular P-selectin (data not shown), indicat-
ing in this experimental model that up-regulation of P-selectin is
complement-dependent and, more specifically, C5a-dependent [24].
ENDOTHELIAL ADHESION MOLECULE
EXPRESSION INDUCED BY TNF-a AND MAC
Besides C5a, MAC was found to be capable of modulating
adhesion molecule expression on endothelial cells. Stimulation
of HUVEC with TNF-a resulted in up-regulation of ICAM-1
and E-selectin [25]. Assembly of sublytic concentrations of
MAC alone on HUVEC did not result in significant up-
regulation of adhesion molecules. However, in the co-presence
of low concentrations of TNF-a, which produced measurable
but limited up-regulation of ICAM-1 and E-selectin, under
similar conditions MAC enhanced TNF-a-dependent up-
regulation of ICAM-1 and E-selectin in a synergistic manner
(Fig. 5). As would be expected, this increased adhesion
molecule expression led to enhanced adhesion of PMN to
HUVEC stimulated with TNF-a together with the MAC when
compared to stimulation with TNF-a or MAC alone (Fig. 6).
Thus, endothelial cells can be stimulated with either C5a or
MAC to bring about direct or indirect up-regulation of endothe-
lial adhesion molecules.
Fig. 3. Neutrophil adhesion to HUVEC stimulated with C5a. Only treatment with an antibody to P-selectin decreased PMN binding to endothelial cells, whereas
blockade of E-selectin, ICAM-1, CD18 or combined blockade of these adhesion molecules (mAb combination) was ineffective.
Fig. 4. Time-course of lung vascular P-selectin expression after systemic
complement activation as detected by binding of a radiolabeled specific
antibody to P-selectin. For the binding index, residual radioactivity in lungs
was compared to radioactivity in the blood obtained at the time of death. As a
negative control of nonspecific binding, the binding of an irrelevant antibody is
depicted.
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NF-KB-DEPENDENT INDUCTION
OF ENDOTHELIAL INTERLEUKIN-8 (IL-8)
AND MONOCYTE CHEMOATTRACTANT
PROTEIN-1 (MCP-1) EXPRESSION BY MAC
Recruitment of neutrophils occurs not only due to engagement
of neutrophil counter-receptors with endothelial adhesion mol-
ecules but also in response to chemokines, which can be
produced by activated endothelial cells and can lead to
stimulation of adherent leukocytes. Assembly of sublytic
concentrations of MAC on HUVEC resulted in generation of
IL-8 and MCP-1 [26], as detected by enzyme-linked immunosor-
bent assay (ELISA; Fig. 7). The promoter regions of genes
responsible for expression of these chemokines are known to be
regulated by the family of NF-kB transcription factors. There-
fore, it was not surprising that assembly of MAC on HUVEC led
to chemokine production via NF-kB activation (translocation to
the nucleus). The maximal translocation of NF-kB clearly
required intact MAC because the absence of C7 in the
formation of MAC abrogated the band shift indicative of the
NF-kB activation. It appears that C5b-8 (MAC-9) is also
capable of activating NF-kB to a limited extent (Fig. 8). As
pointed out above, it is known that C5b-8 has some lytic
properties similar to MAC but that this biological activity is
quantitatively much less than that of MAC. Thus, reduced
activation of NF-kB in HUVEC treated with MAC lacking C9 is
consistent with these earlier observations. In the presence of
the antioxidant, pyrrolidine dithiocarbamate, NF-kB activation
was blocked. Under these conditions, greatly reduced chemo-
kine generation (IL-8, MCP-1) by HUVEC was found (see Fig.
7), indicating that cytosolic to nuclear translocation of NF-kB is
essential for expression of these chemokines and that produc-




BY C5A AND MAC
Other factors that are directly or indirectly involved in neutro-
phil recruitment include products from tissue-based macro-
phages. We investigated in rat alveolar macrophages the extent
of chemokine generation (MIP-2 and CINC as members of the
CXC chemokine family and MIP-1a and MCP-1 representing
CC chemokines) and the way in which complement activation
products might affect this process. C5a or MAC alone caused
little or no chemokine generation in vitro by these cells.
However, the co-presence of a stimulus such as IgG immune
complexes together with either C5a or MAC resulted in greatly
enhanced production of CXC and CC chemokines [B. J.
Czermak, A. B. Lentsch, N. M. Bless, H. Schmal, H. P. Friedl,
and P. A. Ward, unpublished observations]. These data suggest
Fig. 5. Adhesion molecule expression of stimulated HUVEC monolayers.
Stimulation with TNF-a led to an expectable up-regulation of endothelial
ICAM-1. Although MAC by itself had no stimulatory effect, the combination of
TNF-a and MAC resulted in synergistically increased ICAM-1 expression.
Similarly, E-selectin expression, which was inducible by TNF-a, was further
enhanced in the presence of MAC that, when applied alone, seemed inert.
Fig. 6. Neutrophil adhesion to stimulated HUVEC. PMN adhesion caused by
stimulation with TNF-a was further increased in the presence of MAC, whereas
MAC alone had no stimulatory activity.
Fig. 7. Chemokine generation by HUVEC stimulated with MAC. The
MAC-mediated IL-8 and MCP-1 production was strongly diminished by
pretreatment with PTDC, an antioxidant.
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that C5a and MAC (in sublytic composition) function synergis-
tically with a stimulus such as IgG immune complexes to
enhance chemokine generation in vitro.
INDUCTION OF ENDOTHELIAL SUPEROXIDE
PRODUCTION BY C5a
Endothelial cells have been reported to respond to certain
stimuli with the generation of radical oxygen species. C5a (but
not C5ades arg) and TNF-a can each directly induce superoxide
production (O22) by rat pulmonary artery endothelial cells in a
dose-dependent manner [27]. It is interesting to note that the
plateau of the O22 response by C5a-stimulated endothelial cells
was virtually identical to that found with neutrophil responses
to C5a. TNF-a and C5a agonists work via different intracellular
signal transduction pathways. C5a-induced production of O22
was suppressible in the presence of pertussis toxin (Fig. 9),
suggesting a signal transduction pathway involving G proteins.
Similar results were found in the presence of staurosporine,
suggesting involvement of protein kinase C pathway. The
intracellular Ca21 response to a C5a stimulation, as might be
predicted based on the known structure of C5aR (with seven
transmembrane-spanning loops), was also abrogated in the
presence of pertussis toxin or staurosporine. In contrast,
pretreatment of endothelial cells with either pertussis toxin or
staurosporine failed to suppress TNF-a-induced production of
O22 in endothelial cells, confirming that endothelial cell
production of O22 caused by either C5a or TNF-a is running via
different signal transduction pathways.
REQUIREMENT OF COMPLEMENT FOR
UP-REGULATION OF LUNG VASCULAR
ICAM-1 EXPRESSION
The lung model of injury induced by IgG immune complex
deposition in the alveolar space was also evaluated for a
complement requirement. In this model the resulting inflamma-
tory reaction is initiated by alveolar macrophages releasing
early response cytokines such as TNF-a and interleukin-1b
(IL-1b), which leads via endothelial adhesion molecule expres-
sion of ICAM-1 and E-selectin as well as chemokine generation
to neutrophil activation and recruitment into lung. Somewhat
unexpectedly, complement was found to be required for adhe-
sion molecule expression in the lung vasculature as defined
either by complement depletion (with CVF) or by complement
blockade (with sCR1) [28]. Detection of lung vascular ICAM-1
was assessed by binding of labeled antibody to ICAM-1 to the
lung vasculature as well as by immunohistological staining for
ICAM-1 in lung tissue sections. ICAM-1 was up-regulated in
lung injury induced either by IgG immune complex deposition
or after intratracheal instillation of TNF-a. Treatment with
human recombinant sCR-1 decreased ICAM-1 expression by
nearly 50%. Complement depletion before lung injury not only
Fig. 8. NF-kB activation in HUVEC as detected by EMSA analysis. Cells
were stimulated with MAC or MAC components in the absence of C7 or C9 or
with LPS as a positive control (lane 2). Activation of HUVEC by MAC clearly
required insertion into cell membranes because omission of C7 in the assembly
of MAC resulted in no detectable NF-kB translocation. In correlation with
functional aspects, MAC devoid of C9 is capable of NF-kB activation to some
extent, however, to a lesser degree than fully assembled MAC.
Fig. 9. Abrogation of C5a-induced endothelial O22 production by pertussis
toxin (PT). Pretreatment with pertussis toxin reduces O22 generation to a great
extent over a prolonged period of time.
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totally suppressed vascular ICAM-1 up-regulation but de-
creased ICAM-1 levels below that of constitutive expression
(Fig. 10A). The suppression of ICAM-1 up-regulation by
complement depletion was also seen when the inflammatory
reaction was initiated by intratracheal TNF-a instillation (Fig.
10B). Intratracheal blockade of C5a after immune complex
deposition also decreased lung vascular ICAM-1 expression by
over 80% (discussed below, data not shown) [20]. These data
clearly point to a linkage between complement and up-
regulation of lung vascular ICAM-1.
EFFECTS OF ANTI-C5a ON
BRONCHOALVEOLAR LAVAGE
(BAL) TNF-a, VASCULAR LEAKAGE,
AND LUNG MYELOPEROXIDASE (MPO)
Anti-C5a-induced reduction of lung vascular ICAM-1, the
expression of which is known to be TNF-a-regulated, was
hypothesized to be due to an effect of anti-C5a on levels of
TNF-a. TNF-a content in BAL fluids was assessed in animals
undergoing intrapulmonary deposition of IgG immune com-
plexes. As expected, BAL levels of TNF-a in positive controls
were substantially elevated, whereas, in contrast, TNF-a levels
of animals receiving anti-C5a intratracheally were dramatically
reduced (Fig. 11). The treatment with anti-C5a also reduced in
a dose-dependent manner PMN accumulation as well as
vascular permeability. As might be expected in this model, the
intravenous blockade of C5a was not significantly protective
(Fig. 12). In contrast, intravenous administration of anti-C5a
antibody in the CVF model of systemic complement activation
was highly effective in reducing neutrophil buildup and
increases in lung vascular permeability [20].
CONCLUSION
Inflammation-enhancing functions of complement activation
products are diverse based on information obtained from in
vitro and in vivo experiments. Endothelial cells stimulated with
either C5a or MAC react with adhesion molecule expression
(P-selectin) and in the presence of an additional stimulus (e.g.,
TNF-a) exhibit synergistic expression of E-selectin and ICAM-1.
Generation of O22 by endothelial cells occurs after stimulation
with C5a. MAC can also cause chemokine generation in
endothelial cells in a NF-kB-dependent manner. Macrophages
react to the co-presence of C5a or MAC and IgG immune
complexes with synergistically increased chemokine produc-
tion. Complement activation products in in vivo inflammatory
reactions can directly stimulate adhesion molecule expression
by endothelial cells and early response cytokines and the
generation of chemokines, thereby promoting proinflammatory
mechanisms at several levels.
Inhibition of the complement system can work as a powerful
anti-inflammatory intervention. If control of complement activa-
tion is to be achieved by inhibition of a single mediator of the
complement cascade, C5a seems to be one attractive target. The
blockade of C5a, a major player in proinflammatory mecha-
nisms, does not affect other important functions of the comple-
ment system such as opsonization and lysis of bacteria. The
Fig. 10. Lung vascular ICAM-1 up-regulation after alveolar IgG immune complex deposition (A) or intratracheal instillation of TNF-a (B). Complement depletion
by repetitive CVF administration not only inhibited ICAM-1 up-regulation but resulted in lower than constitutively expressed ICAM-1 levels in the IgG model of lung
injury. Similarly, complement depletion abrogated lung vascular ICAM-1 up-regulation completely in animals undergoing intratracheal treatment with TNF-a.
Competitive blockade of CR1 by exogenous administration of sCR1 decreased IgG immune complex-induced ICAM-1 up-regulation by 50%.
Fig. 11. Bronchoalveolar TNF-a levels after alveolar IgG immune complex
deposition. Intratracheal treatment with anti-C5a resulted in TNF-a levels that
were indistinguishable from negative control values.
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distinct anti-inflammatory effects of complement blockade or
inhibition are very much dependent on choosing the right time
frame and the appropriate conditions for intervention. It will be
essential to have such information if there are to be useful
clinical applications of complement inhibition. The presented
data point to complex and diverse pathways leading to inflam-
matory responses that depend directly or indirectly on comple-
ment activation products. This suggests that inhibition or
blockade of complement and/or its activation products may be
useful in the treatment of human inflammatory conditions.
REFERENCES
1. Quezado, Z. M., Hoffman, W. D., Winkelstein, J. A., Yatsiv, I., Koev, C. A.,
Cork, L. C., Elin, R. J., Eichacker, P. Q., Natanson, C. (1994) The third
component of complement protects against Escherichia coli endotoxin-
induced shock and multiple organ failure. J. Exp. Med. 179, 569–578.
2. Fischer, M. B., Prodeus, A. P., Nicholson-Weller, A., Ma, M., Murrow, J.,
Reid, R. R., Warren, H. B., Lage, A. L., Moore, F. D., Rosen, F. S., Carroll,
M. C. (1997) Increased susceptibility to endotoxin shock in complement
C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J.
Immunol. 159, 976–982.
3. May, J. E., Kane, M. A., Frank, M. M. (1972) Host defense against bacterial
endotoxemia—contribution of the early and late components of comple-
ment to detoxification. J. Immunol. 109, 893–895.
4. Wessels, M. R., Butko, P., Ma, M., Warren, H. B., Lage, A. L., Carroll, M. C.
(1995) Studies of group B streptococcal infection in mice deficient in
complement component C3 or C4 demonstrate an essential role for
complement in both innate and acquired immunity. Proc. Natl. Acad. Sci.
USA 92, 11490–11494.
5. Johnson, K. J., Ward, P. A. (1971) Protective function of C6 in rabbits
treated with bacterial endotoxin. J. Immunol. 106, 1125–1127.
6. Barton, P. A., Warren, J. S. (1993) Complement component C5 modulates
the systemic tumor necrosis factor response in murine endotoxic shock.
Infect. Immun. 61, 1474–1481.
7. Wang, Y., Hu, Q., Madri, J. A., Rollins, S. A., Chodera, A., Matis, L. A.
(1996) Amelioration of lupus-like autoimmune disease in NZB/WF1 mice
after treatment with a blocking monoclonal antibody specific for comple-
ment component C5. Proc. Natl. Acad. Sci. USA 93, 8563–8568.
8. Wang, Y., Rollins, S. A., Madri, J. A., Matis, L. A. (1995) Anti-C5
monoclonal antibody therapy prevents collagen-induced arthritis and
ameliorates established disease. Proc. Natl. Acad. Sci. USA 92, 8955–
8959.
9. Kroshus, T. J., Rollins, S. A., Dalmasso, A. P., Elliott, E. A., Matis, L. A.,
Squinto, S. P., Bolman, R. M., 3rd (1995) Complement inhibition with an
anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex
vivo model of pig-to-human xenotransplantation. Transplant. 60, 1194–
1202.
10. Ward, P. A., Zwaivler, N. J. (1973) Quantitative phagocytosis by neutro-
phils. II. Release of the C5-cleaving enzyme and inhibition of phagocytosis
by rheumatoid factor. J. Immunol. 111, 1777–1782.
11. Hill, J. H., Ward, P. A. (1969) C3 leukotactic factors produced by a tissue
protease. J. Exp. Med. 130, 505–518.
12. Ward, P. A., Chapitis, J., Conroy, M. C., Lepow, I. H. (1973) Generation by
bacterial proteinases of leukotactic factors from human serum and C3 and
C5. J. Immunol. 110, 1003–1009.
13. Foreman, K. E., Vaporciyan, A. A., Bonish, B. K., Jones, M. L., Johnson,
K. J., Glovsky, M. M., Eddy, S. M., Ward, P. A. (1994) C5a-induced
expression of P-selectin in endothelial cells. J. Clin. Invest. 94, 1147–1155.
14. Morgan, B. P. (1989) Complement membrane attack on nucleated cells:
resistance, recovery and non-lethal effects. Biochem. J. 264, 1–14.
15. Podack, E. R. (1988) Cytolytic Lymphocytes and Complement. (E. R.
Podack, ed.) Boca Raton, FL: CRC Press, 173–184.
16. Ramm, L. E., Whitlow, M. B., Mayer, M. M. (1985) The relationship
between channel size and number of C9 molecules in the C5b-9 complex.
J. Immunol. 134, 2594–2599.
17. Stewart, J. L., Monahan, J. B., Brickner, A., Sodetz, J. M. (1984)
Measurement of the ratio of the eight and ninth components of human
complement on complement-lysed membranes. Biochemistry 23, 4016–
4022.
18. Langlois, P. F., Gawryl, M. S. (1988) Accentuated formation of the terminal
C5b-9 complement complex in patient plasma precedes development of
the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 138,
368–375.
19. Perkinson, D. T., Baker, P. J., Couser, W. G., Johnson, R. J., Adler, S. (1985)
Membrane attack complex deposition in experimental glomerular injury.
Am. J. Pathol. 120, 121–128.
20. Mulligan, M. S., Schmid, E., Beck-Schimmer, B., Till, G. O., Friedl, H. P.,
Brauer, R. B., Hugli, T. E., Miyasaka, M., Warner, R. L., Johnson, K. J.,
Ward, P. A. (1996) Requirement and role of C5a in acute lung inflammatory
injury in rats. J. Clin. Invest. 98, 503–512.
21. Schmid, E., Warner, R. L., Crouch, L. D., Friedl, H. P., Till, G. O., Hugli,
T. E., Ward, P. A. (1997) Neutrophil chemotactic activity and C5a following
systemic activation of complement in rats. Inflammation 21, 325–333.
22. Hattori, R., Hamilton, K. K., McEver, R. P., Sims, P. J. (1989) Complement
proteins C5b-9 induce secretion of high molecular weight multimers of
endothelial von Willebrand factor and translocation of granule membrane
protein GMP-140 to the cell surface. J. Biol. Chem. 264, 9053–9060.
23. Mulligan, M. S., Polley, M. J., Bayer, R. J., Nunn, M. F., Paulson, J. C.,
Ward, P. A. (1992) Neutrophil-dependent acute lung injury, requirement
for P-selectin (GMP-140). J. Clin. Invest. 90, 1600–1607.
Fig. 12. Lung injury parameters after alveolar IgG immune complex deposition. The permeability index (A) as a measure of vascular leakage and MPO contents of
lung extracts (B) indicating PMN accumulation decreased significantly after intratracheal treatment with anti-C5a in a dose-dependent manner.
Czermak et al. Complement and inflammation 47
24. Mulligan, M. S., Schmid, E., Till, G. O., Hugli, T. E., Friedl, H. P., Roth,
R. A., Ward, P. A. (1997) C5a-dependent upregulation in vivo of lung
vascular P-selectin. J. Immunol. 158, 1857–1861.
25. Kilgore, K. S., Shen, J. P., Miller, B. F., Ward, P. A., Warren, J. S. (1995)
Enhancement by the complement membrane attack complex of TNFa-
induced endothelial cell expression of E-selectin and ICAM-1. J. Immu-
nol. 155, 1434–1441.
26. Kilgore, K. S., Schmid, E., Shanley, T. P., Flory, C. M., Maheswari, V.,
Tramontini, N. L., Cohen, H., Ward, P. A., Friedl, H. P., Warren, J. S. (1997)
Sublytic concentrations of the membrane attack complex (MAC) of
complement induce endothelial interleukin 8 (IL-8) and monocyte protein
1 (MCP-1) through nuclear factor-kB activation. Am. J. Pathol. 150,
2019–2031.
27. Murphy, H. S., Shayman, J. A., Till, G. O., Maroughui, M., Owens, C. B.,
Ryan, U. S., Ward, P. A. (1992) Superoxide responses of endothelial cells to
C5a and TNFa: divergent signal transduction pathways. Am. J. Physiol.
263, L51–L59.
28. Vaporciyan, A. A., Mulligan, M. S., Warren, J. S., Barton, P. A., Miyasaka,
M., Ward, P. A. (1995) Up-regulation of lung vascular ICAM-1 in rats is
complement dependent. J. Immunol. 155, 1442–1449.
48 Journal of Leukocyte Biology Volume 64, July 1998
